CurrentCignaPolicy N/A

Cystic Fibrosis - Bronchitol Prior Authorization Policy

Defines prior authorization requirements and medical necessity criteria for Bronchitol (inhaled mannitol) for adults with cystic fibrosis under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyCystic Fibrosis - Bronchitol Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateFeb 11, 2026

Key ActionObtain prior authorization and approve for 1 year when all FDA-approved indication criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥18minimum age for approval

1 yearapproval duration

Prior Authauthorization requirement

No hypertonic saline usenot covered condition

Coverage Criteria for Bronchitol (inhaled mannitol)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Cystic Fibrosis - Initial Approval

A) Patient is ≥ 18 years of age
B) Patient has tried hypertonic saline
C) Patient has passed the Bronchitol Tolerance Test
D) Patient will pre-medicate with a short-acting bronchodilator
E) The medication is prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Recommended

Prior Authorization is recommended. Approvals are granted for 1 year when FDA‑approved indication criteria are met and the prescriber is a pulmonologist or physician who specializes in cystic fibrosis.

Approve for 1 year when ALL FDA‑approved indication criteria are met
Prescriber requirement: prescribed by or in consultation with a pulmonologist or CF specialist

Step Therapy

Required Prior Therapy (Step Therapy)

Patient must have tried hypertonic saline prior to approval for Bronchitol (mannitol oral inhalation powder).

Documented trial of hypertonic saline prior to initiating Bronchitol
Concomitant use with hypertonic saline is not covered

Documentation Required

Required Clinical Documentation

Clinical documentation must support that the patient has passed the Bronchitol Tolerance Test and will pre‑medicate with a short‑acting bronchodilator. The tolerance test must be performed under supervision capable of managing acute bronchospasm. Include documentation of the tolerance test result, who performed it, and details of pre‑medication.

Document Bronchitol Tolerance Test pass result and supervising clinician
Document administration of a short‑acting bronchodilator 5–15 minutes prior to each dose (pre‑medication plan)
Record that the tolerance test was performed in a setting able to manage acute bronchospasm

Denial Risk

Triggers for Denial

Denial may be triggered if required criteria or documentation are not met. Review these conditions before submission to avoid delays or denial.

Patient age < 18 years (policy requires ≥ 18)
No documented trial of hypertonic saline prior to Bronchitol
Failed Bronchitol Tolerance Test or no documentation of a passed tolerance test
No documentation of pre‑medication with a short‑acting bronchodilator (5–15 minutes prior)
Concomitant use with hypertonic saline (not covered)
Prescriber is not a pulmonologist or physician who specializes in cystic fibrosis and no documented consultation

Key Definitions

Bronchitol Tolerance Test — definition and implications

DefinitionA supervised test administered to identify bronchial hyperresponsiveness to inhaled mannitol; performed under supervision of a healthcare practitioner able to manage acute bronchospasm.

Purpose/ImplicationIdentifies patients who are suitable candidates for Bronchitol maintenance therapy; only adults who pass the test should receive Bronchitol.

ContraindicationFailure to pass the Bronchitol Tolerance Test contraindicates Bronchitol therapy due to risk of bronchospasm.

Testing environment requirementMust be performed under supervision of a practitioner able to manage acute bronchospasm.

Pre-medication recommendationA short-acting bronchodilator should be administered by oral inhalation 5 to 15 minutes before every dose of Bronchitol.

Background

Bronchitol (inhaled dry powder mannitol) is indicated as an add‑on maintenance therapy to improve pulmonary function in adults aged ≥ 18 years with cystic fibrosis. Because Bronchitol can cause bronchospasm, a supervised Bronchitol Tolerance Test is required before treatment and pre‑medication with a short‑acting bronchodilator is recommended. Prior authorization is recommended and approvals are issued for 1 year when all FDA‑approved indication criteria are met.